Risk for candidiasis is increased in patients receiving anti-IL-17 reagents, resulting in adjusted incidence rates of 0.4–2.2/100 patient-years.106,123 This is probably due to the central role of IL-17 in the defence against fungal infections.124 Of note, candidiasis in this setting is usually mild and does not lead to treatment discontinuation. This evidence concerns the gene IL17A and Candidiasis, Invasive.